Tag: CLI
Micro Medical Solutions completes enrolment for STAND MicroStent trial
Micro Medical Solutions (MMS), an innovator in the field of microvascular intervention to improve clinical outcomes and quality of life in patients with chronic...
Promising future previewed for PAD treatment at Riga summit
This advertorial is sponsored by BD.
There has been major progress in the treatment of peripheral arterial disease (PAD) globally in the last few years,...
BEST-CLI attracts US$3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a US$3.3 million contribution toward the BEST-CLI (Best endovascular versus best surgical therapy in patients with critical limb...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
Lack of access to vascular specialists creates major disparities in amputation...
Speaking on current trends in amputation rates with critical limb-threatening ischaemia (CLTI) patients, Misty Humphries (Sacramento, USA) tells Vascular News that while Medicare data shows that amputation rates...
New tools for CLTI: ISET audience hear what’s on the horizon...
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...
New tools for CLTI: ISET audience hear what’s on the horizon...
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...
Introduction of dedicated vascular limb salvage clinic improves one-year amputation outcomes...
One-year outcomes of patients with chronic-limb threatening ischaemia (CLTI) treated in an outpatient-based vascular limb salvage clinic show an improved rate of major amputation....
Novel PAD treatment may be more cost-effective than standard care, study...
FlowOx therapy (Otivio) delivered as a single annual dose may be a cost-effective treatment for peripheral arterial disease (PAD), a recent study published in...
CONSEQUENT study shows low mortality and TLR rates in PAD patients...
NOTE: This video is ONLY available to watch in selected countries and geographies
Ralf Langhoff (Berlin, Germany) talks to Vascular News about the 12-month...
The CLI Global Society announces the Journal of Critical Limb Ischemia
The CLI Global Society is launching the first peer-reviewed academic journal focusing on interventional techniques pertaining to critical limb ischemia (CLI). The new journal,...
The CLI Global Society announces the Journal of Critical Limb Ischemia
The CLI Global Society is launching the first peer-reviewed academic journal focusing on interventional techniques pertaining to critical limb ischemia (CLI). The new journal,...
IN.PACT Global study shows DCB “safe and effective” in clinically-complex CLI...
Michel Reijnen (Arnhem, Netherlands) talks to Vascular News about the four-year IN.PACT Global study results, focusing on the 156 patients in the study who...
LINC 2021: New data show potential of Limflow system to improve...
In a late-breaking trial session at LINC 2021 (The Leipzig Interventional Course, 25–29 January, online), key updates on below-the-knee (BTK) interventions were in the spotlight. Speaking during his...
CDC recognises and codifies critical limb-threatening ischaemia in ICD-10-CM
A coalition organised by the CLI Global Society has announced its proposal to distinctly recognise "critical limb ischaemia" (CLI) and "chronic limb-threatening ischaemia" (CLTI)...
CDC recognises and codifies critical limb-threatening ischaemia in ICD-10-CM
A coalition organised by the CLI Global Society has announced its proposal to distinctly recognise "critical limb ischaemia" (CLI) and "chronic limb-threatening ischaemia" (CLTI)...
Pedal artery revascularisation: Is it ready for prime time?
Reviewing the available evidence for below-the-ankle interventions in the treatment of critical limb-threatening ischaemia (CLTI), Srini Tummala proposes that pedal artery intervention “should be...
First US commercial use of Tack Endovascular System (4F) in BTK...
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the USA. Notably the first FDA-approved...
First US commercial use of Tack Endovascular System in BTK arteries...
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the USA. Notably the first FDA-approved...
Hospitals face “real challenge” of finding sensible solutions to treat CLI...
Recently appointed chair of the Circulation Foundation, Rachel Bell (London, UK), talks to BLearning at VSASM 2019 (Vascular Societies’ Annual Scientific Meeting; 27–29 November, Manchester, UK) about the role...
LINC 2020: Profusa Lumee oxygen platform may improve clinical management of...
Profusa has announced research findings that suggest the company's Lumee oxygen platform may help improve the clinical management of patients with critical limb ischaemia...
LINC 2020: Profusa Lumee oxygen platform may improve clinical management of...
Profusa has announced research findings that suggest the company's Lumee oxygen platform may help improve the clinical management of patients with critical limb ischemia...
Profusa wins CE mark approval for real-time tissue oxygen monitoring platform
Profusa has announced that it has received Conformité Européenne (CE) mark approval to market its Wireless Lumee Oxygen platform for continuous, real-time monitoring of...
Phase III SALAMANDER trials of Rexgenero’s REX-001 open and recruiting patients...
The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischemia (CLI) using a novel patient-specific regenerative therapy has...
Full revascularisation “may not be the best solution” for CLI patients
Aiming for full revascularisation “may not be the best solution” for treating patients with critical limb ischaemia (CLI) according to Thomas Zeller (Bad Krozingen,...
More focus needed on best medical therapy and perfusion imaging for...
Curiously, the mortality risk for patients with critical limb ischaemia (CLI) has not changed over the last few decades, despite advances in cardiovascular medicine...
CLI: “Know the patient, know the disease and know what you...
Bruce Gray (Greenville, USA) talks to Vascular News after winning the LIVE (Leader In EndoVascular Education) award at VIVA 2019 (4–7 November, Las Vegas,...
CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...
NOTE: ONLY intended for healthcare professionals outside of the USA and France.
Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...
First patient enrolled in Cook Regentec’s clinical trial of investigational therapy...
Cook Regentec has announced enrolment of the first patient in an international clinical trial evaluating the HemaTrate Blood Filtration System to treat patients with...
Cell therapy may provide benefit for “no option” critical limb ischaemia...
Two-year results from the MOBILE (Marrowstim treatment of limb ischaemia in patients with severe peripheral arterial disease) trial indicate that injecting concentrated bone marrow...
Cell therapy may provide benefit for “no option” critical limb ischaemia...
Two-year results from the MOBILE (Marrowstim treatment of limb ischaemia in patients with severe peripheral arterial disease) trial indicate that injecting concentrated bone marrow...
Intraoperative oxygen monitoring predicts wound healing in critical limb ischaemia patients...
Preliminary findings from an initial study with 25 patients have shown that measuring the changes in oxygen concentration at baseline, during, and after endovascular...
The reactive and repetitive multidisciplinary CLI team
It is imperative that every medical institution has an interdisciplinary CLI team, argues Jihad Mustapha. Here, he exhorts the benefits of working in such...
Rexgenero expands manufacturing of REX-001 cell-based CLI therapy
Rexgenero, a regenerative medicine company developing advanced cell-based therapies to treat critical limb ischaemia (CLI), has announced that it has successfully expanded manufacturing of...
New update on Phase III clinical trials of REX-001 cell-based therapy...
Rexgenero, a regenerative medicine company working to develop cell-based therapies to treat critical limb ischaemia (CLI), has presented an update on its two Phase...
VIVA 2018 focuses on the critical issues in vascular medicine
In the arterial space, VIVA 2018 focused on the fact that there is an increasing awareness of limb threatening ischaemia coupled with an increase...
Lutonix BTK IDE: First Level 1 evidence of positive safety and...
Patrick Geraghty (St Louis, USA) presented new datapoints from the six-month outcomes of the Lutonix BTK IDE trial at the 2018 VEITHsymposium (13–17 November,...
Lutonix 014 DCB gathers first randomised evidence of positive safety and...
Six-month outcomes of the Lutonix BTK IDE trial, a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (DCB; BD), has demonstrated that...
Peripheral arterial disease patients at increased risk for high opioid use
Patients with peripheral arterial disease (PAD) are found to have an increased risk for high opioid use. Nathan Itoga and colleagues from the University...
First-ever CE mark of a bioresorbable scaffold for below-the-knee PAD
Reva Medical, a company developing bioresorbable polymer technologies for vascular applications, has announced that its Motiv bioresorbable scaffold is the first drug-eluting bioresorbable scaffold...
Intraoperative oxygen monitoring predicts wound healing in critical limb ischaemia patients...
Preliminary findings from an initial study with 25 patients have shown that measuring the changes in oxygen concentration at baseline, during, and after endovascular...
LimFlow completes enrolment in US feasibility study
LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....
LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...
Medtronic added to its body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes...
New analysis suggests peripheral artery disease affects 42–60 million Chinese citizens
A new analysis published by The Sage Group has concluded that 42–60 million Chinese citizens are afflicted by peripheral artery disease (PAD), with 5.6–6.3...
Intact Vascular announces enrolment of first European patient in TOBA II...
Intact Vascular’s TOBA II BTK (Tack optimized balloon angioplasty II below the knee) clinical trial has commenced enrolment in Europe, with the first patient treated by Marianne Brodmann and Peter Reif...
First patient treated in LimFlow US feasibility study as international post-market...
LimFlow SA has announced enrolment of the first patient in the US feasibility study of the LimFlow percutaneous deep vein arterialisation (pDVA) system, a novel,...
FDA approves six-month primary endpoint for Tack endovascular system in below-the-knee...
The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint in Intact Vascular’s TOBA II...
Endovascular therapy for critical limb ischaemia: When is enough, enough?
We need to stop doing endovascular procedures for critical limb ischaemia patients when no measurable benefit is being seen and when the adverse event rate is...
Surgery-first approach for CLI offers faster wound healing rate than endovascular...
A surgical-first strategy appears to be superior to endovascular treatment for critical limb ischaemia (CLI) revascularisation, exhibiting improved wound healing rate and overall healing...
Autologous bone marrow cell injection reduces one-year amputation rate for Rutherford...
Fifty-two-week outcomes of the MOBILE trial indicate a “significant reduction in major amputations” among Rutherford 4 and non-diabetic Rutherford 5 critical limb ischaemia patients...
Cardiovascular Systems releases 30-day results from LIBERTY 360° study
Cardiovascular Systems has released procedural and 30-day results from its LIBERTY 360° study in a late-breaking presentation at the 2016 Amputation Prevention Symposium (AMP;...
